Delia Cinteza1, Mihai Berteanu1, Suzana Vladoiu2, Bogdan Nicolae Manolescu3, Horatiu Dinu4. 1. "Carol Davila" University of Medicine and Pharmacy, Faculty of Medicine, Department of Rehabilitation and Physical Medicine, Bucharest, Romania. 2. "C.I. Parhon" National Institute of Endocrinology, Scientific Research Department, Bucharest, Romania. 3. Polytechnic University of Bucharest, Faculty of Applied Chemistry and Science of Materials, Department of Organic Chemistry "C.D. Nenitescu", Bucharest, Romania. 4. ELIAS Emergency University Hospital, Department of Rehabilitation and Physical Medicine, Bucharest, Romania.
Abstract
OBJECTIVES: Stroke is followed by an inflammatory response lasting up to several months. Moreover, many of the stroke-related comorbidities (i.e., diabetes mellitus, dyslipidemia, cardiovascular disease, and atherosclerosis) are characterized by an pro-inflammatory status. MATERIAL AND METHODS: We designed this pilot study to evaluate the relation between the consumption of a nutritional supplement (ALAnerv®) and the dynamic of the inflammatory status in post-acute stroke patients undergoing rehabilitation. The study population comprised 28 patients which were assigned into two study groups, named (-) ALA and (+) ALA. All subjects followed the same rehabilitation program. There were no significant differences in respect to the standard medication between the groups. Moreover, patients from the (+) ALA group received ALAnerv® for two weeks (2 pills/day). We assessed IL-1α, IL-6, TNF-α, sICAM-1, and myeloperoxidase in blood samples taken at the beginning and at the end of the study period. OUTCOMES: In the (+) ALA group only IL-1α (- 9.9% ± 3.7, P = 0.013) and IL-6 (- 26.5% ± 8.2, P = 0.003) significantly decreased during the study period. The multiple regression analysis indicated that the ALAnerv® treatment was responsible for the significant decrease of IL-6 level (P = 0.008). Moreover, the percentage of IL-6 variation between the study groups reached statistical significance (8.4% ± 11.5 vs. - 26.5% ± 8.2, P = 0.034). CONCLUSIONS: These results indicate that ALAnerv® could be beneficial for the correction of the inflammatory status in post-acute stroke patients and underline the need of a longer treatment period with a higher dose.
OBJECTIVES:Stroke is followed by an inflammatory response lasting up to several months. Moreover, many of the stroke-related comorbidities (i.e., diabetes mellitus, dyslipidemia, cardiovascular disease, and atherosclerosis) are characterized by an pro-inflammatory status. MATERIAL AND METHODS: We designed this pilot study to evaluate the relation between the consumption of a nutritional supplement (ALAnerv®) and the dynamic of the inflammatory status in post-acute strokepatients undergoing rehabilitation. The study population comprised 28 patients which were assigned into two study groups, named (-) ALA and (+) ALA. All subjects followed the same rehabilitation program. There were no significant differences in respect to the standard medication between the groups. Moreover, patients from the (+) ALA group received ALAnerv® for two weeks (2 pills/day). We assessed IL-1α, IL-6, TNF-α, sICAM-1, and myeloperoxidase in blood samples taken at the beginning and at the end of the study period. OUTCOMES: In the (+) ALA group only IL-1α (- 9.9% ± 3.7, P = 0.013) and IL-6 (- 26.5% ± 8.2, P = 0.003) significantly decreased during the study period. The multiple regression analysis indicated that the ALAnerv® treatment was responsible for the significant decrease of IL-6 level (P = 0.008). Moreover, the percentage of IL-6 variation between the study groups reached statistical significance (8.4% ± 11.5 vs. - 26.5% ± 8.2, P = 0.034). CONCLUSIONS: These results indicate that ALAnerv® could be beneficial for the correction of the inflammatory status in post-acute strokepatients and underline the need of a longer treatment period with a higher dose.
Authors: U Waje-Andreassen; J Kråkenes; E Ulvestad; L Thomassen; K-M Myhr; J Aarseth; C A Vedeler Journal: Acta Neurol Scand Date: 2005-06 Impact factor: 3.209
Authors: Hedley C A Emsley; Craig J Smith; Carole M Gavin; Rachel F Georgiou; Andy Vail; Elisa M Barberan; John M Hallenbeck; Gregory J del Zoppo; Nancy J Rothwell; Pippa J Tyrrell; Stephen J Hopkins Journal: J Neuroimmunol Date: 2003-06 Impact factor: 3.478